Search
SARS-CoV-2 Sclamp
go.drugbank.com/drugs/DB15849InvestigationalAs of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932).
Danegaptide
go.drugbank.com/drugs/DB11821InvestigationalDanegaptide has been investigated for the treatment of Focus of Study is STEMI.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalOSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...
Voglibose
go.drugbank.com/drugs/DB04878InvestigationalVoglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
Omburtamab
go.drugbank.com/drugs/DB15635InvestigationalCD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
RTP-801i
go.drugbank.com/drugs/DB06048InvestigationalRTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...
Teglarinad chloride
go.drugbank.com/drugs/DB05217InvestigationalGMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond....
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalRimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell...
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalThis organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants.